/
Nephrology
Iga Nephropathy
38
Pipeline Programs↗
52
Active Trials↗
35
Companies Involved↗
IgA Nephropathy is a moderately active landscape with 38 programs across 35 companies. The most active players are Novartis, Travere Therapeutics, Inc., Otsuka. 16 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 29
Phase 316
Approved
No programs
Analysis
Modality Breakdown
92%
Small molecule
33 of 36 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 97% of 38 pipeline programs.
Analysis
Trial Status
116
clinical trials
Completed33 · 28%
Recruiting21 · 18%
Not yet recruiting17 · 15%
Unknown status17 · 15%
Active, not recruiting12 · 10%
Terminated8 · 7%
Other8 · 7%
Clinical Trials
Trial Activity
116 trials
Development and Validation of a Gd-IgA1 Guided Precision Therapy System for Targeted Therapeutic Strategies of IgA Nephropathy： An Open-label, Random Controlled Trial
Recruiting·—·Preclinical·NCT07822100·374 enrolled
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
Recruiting·RRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.·Phase 2·NCT07305974·30 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)